OJOG  Vol.3 No.10 , December 2013
Neuroendocrine tumors of the ovary: What support?
ABSTRACT

Neuroendocrine tumors of the ovary tumors are little known and infrequent. They are made up of cells appearing in the endocrine and nervous systems. These tumors are rare, but most of them are very aggressive, especially when they are diagnosed beyond FIGO Stage I. The distinction among the different subtypes is difficult and requires efficient techniques. Symptoms of neuroendocrine tumors are often nonspecific (redness in the face, diarrhea, asthma, abdominal pain and etc.,) and confused with more common diseases. Misdiagnosis is often asked: menopause or irritable bowel syndrome. Often the correct diagnosis is not made until years after the onset of symptoms. The relative rarity of these diseases and the lack of specificity of the symptoms make them often be diagnosed several years after onset. Fortunately, science has made significant advances in the diagnosis and treatment of neuroendocrine tumors. We report the case of a woman of 54 years, with abdominopelvic mass, in whom abdominal ultrasound revealed a mass avascular tissue Doppler taking the screen. The abdominopelvic CT showed a large cystic mass solido—abdominopelvic whose origin is difficult to determine. The patient underwent an exploratory laparotomy. Anapath the results of the right ovary were in favor of a well-differentiated neuroendocrine lesion.


Cite this paper
Moubaker, H. , Errarhay, S. , Mahmoud, S. , Bennani, A. , Bouchikhi, C. , Amarti, A. and Banani, A. (2013) Neuroendocrine tumors of the ovary: What support?. Open Journal of Obstetrics and Gynecology, 3, 739-742. doi: 10.4236/ojog.2013.310136.
References
[1]   Capella, C., Heitz, P.U., Hoffler, H., Solcia, E. and Kloppel, G. (1995) Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Archiv, 425, 547-560. http://dx.doi.org/10.1007/BF00199342

[2]   Pearse, A.G.E. (1969) The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series, and the embryologic, physiologic and pathologic implications of the concept. Journal of Histochemistry & Cytochemistry, 17, 303-313. http://dx.doi.org/10.1177/17.5.303

[3]   Le Douarin, N.M., Teillet, M.A. and Couly, G. (1990) Chimères embryonnaireset développement du système nerveux. Medecine Sciences, 6, 228-244.

[4]   Andrew, A., Kramer, B. and Rawdon, B. (1998) The origin of gut and pancreatic neuroendocrine (APUD) cellsthe last word? The Journal of Pathology, 186, 117-118. http://dx.doi.org/10.1002/ (SICI)1096-9896(1998100)186:2<117::AID-PATH152>3.0.CO;2-J

[5]   Lechago, J. and Gould, V.E. (1997) Blood worth’s endocrine pathology, 3rd Edition, Williams & Wilkins, Baltimore.

[6]   Saint-André, J.P., Valo, I. and Guyétant, S. (2000) Immunohistochimie des tumeurs neuro-endocrines. Annales de Pathologie, 20, S129-31.

[7]   Oda, Y., Tanaka, Y., Naruse, T., Sasanabe, R., Tsubamoto, M. and Funahashi, H. (2002) Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. Surgery Today, 32, 690-694. http://dx.doi.org/10.1007/s005950200128

[8]   Hauser, H., Wolf, G., Uranus, S. and Klimpfinger, M. (1995) Neuroendocrine tumours in various organ systems in a ten-year period. European Journal of Surgical Oncology, 21, 297-300.
http://dx.doi.org/10.1016/S0748-7983(95)91624-5

[9]   Modlin, I.M. and Sandor, A. (1997) An analysis of 8305 cases of carcinoid tumors. Cancer, 79, 813-829. http://dx.doi.org/10.1002/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2

[10]   Williams, E.D. and Sandler, M. (1963) The classification of carcinoid tumours. Lancet, 281, 238-239. http://dx.doi.org/10.1016/S0140-6736(63)90951-6

[11]   Travis, W.D., Colby, T.V., Corrin, B., et al. (1999) Histological typing of lungand pleural tumours. WHO International Histological Classificationof Tumours, Springer, Berlin. http://dx.doi.org/10.1007/978-3-642-60049-4

[12]   Solcia, E., Kloppel, G. and Sobin, L.H. (2000) Histological typing of endocrine tumours. WHO International Histological Classification of Tumours. Springer, Berlin. http://dx.doi.org/10.1007/978-3-642-59655-1

[13]   Capella, C., Sessa, F., Cornaggia, M., La Rosa, S. and Uccella, S. (1999) Mixedexocrine-endocrine tumors of the gastro-intestinal tract. Revista espanola de Patología, 32, 466-467.

[14]   Heymann, M.F., Joubert, M., Nemeth, J., Franc, B., Visset, J., Hamy, A., le Borgne, J., le Neel, J.C., Murat, A., Cordel, S. and le Bodic, M.F. (2000) Prognostic and immunohistochemical validation of the Capella classification of pancreatic neuroendocrine tumours: An analysis of 82 sporadic cases. Histopathology. 36, 421-432. http://dx.doi.org/10.1046/j.1365-2559.2000.00892.x

[15]   Gumbs, A.A., Moore, P.S., Falconi, M. Bassi, C., Beghelli, S., Modlin, I. and Scarpa, A. (2002) Review of the clinical, histological and molecular aspects of pancreatic endocrine neoplasms. Journal of Surgical Oncology, 81, 45-53. http://dx.doi.org/10.1002/jso.10142

[16]   Le Bodic, M.F., Heymann, M.F., Lecomte, M., Berger, N., Berger, F., Louvel, A., De Micco, C., Patey, M., De Mascarel, A., Burtin, F. and Saint-Andre, J.P. (1995) Immuno-histochemical study of 100 pancreatic tumors in 28 patients with Multiple Endocrine Neoplasia type 1. The American Journal of Surgical Pathology, 20, 1378-1384. http://dx.doi.org/10.1097/00000478-199611000-00009

[17]   Komminoth, P. (1999) Review: Multiple endocrine neoplasia type 1, sporadic neuroendocrine tumors, and MENIN. Diagnostic Molecular Pathology, 8, 107-112. http://dx.doi.org/10.1097/00019606-1999 09000-00001

[18]   Matias-Guiu, X. (1998) RET protooncogene analysis in the diagnosis ofmedullary thyroid carcinoma and muliple endocrine neoplasiatype II. Advances in Anatomic Pathology, 5, 196-201.
http://dx.doi.org/10.1097/00125480-199805000-00058

 
 
Top